Hydroxychloroquine appears to be a safe and effective treatment option for anogenital lichen sclerosus that only has mild adverse effects, according to a study. Christeebella O. Akpala and colleagues analyzed the demographic characteristics, clinicopathological features, treatment response, and outcomes of 70 patients diagnosed with either anogenital or extragenital lichen sclerosus who received hydroxychloroquine therapy (2018 to 2023). The researchers found that 36% of patients had a connective tissue disorder, prompting hydroxychloroquine therapy. Of the 30 patients treated solely for lichen sclerosus, 21 showed a response, and nine had no response. The overall response among those with anogenital lichen sclerosus was...